Medicamen Biotech Ltd

As of November 14, 2025, Medicamen Biotec is considered expensive and overvalued with a PE ratio of 58.40 and an EV to EBITDA of 38.85, despite a slight improvement in valuation grade, as evidenced by its poor stock performance of -19.84% year-to-date compared to the Sensex's 8.22% gain.

As of November 14, 2025, Medicamen Biotec is considered overvalued with a PE ratio of 58.40, significantly higher than peers like Sun Pharma and Cipla, and has underperformed the Sensex with a year-to-date return of -19.84%.

As of November 14, 2025, Medicamen Biotec is considered expensive with a PE ratio of 58.40 and an EV to EBITDA of 38.85, indicating overvaluation compared to peers and a year-to-date stock performance of -19.84% against the Sensex's 8.22%.

Medicamen Biotec's historical performance shows a decline in net sales from 179.31 Cr in March 2024 to 162.55 Cr in March 2025, with a drop in operating profit and profit after tax, while total assets and liabilities slightly increased. Cash flow from operating activities remained negative at -6.00 Cr for both years.

As of November 13, 2025, Medicamen Biotec is considered very expensive and overvalued, with a PE ratio of 59.70, significantly higher than peers like Sun Pharma and Cipla, and despite a recent short-term gain, it has declined 18.07% year-to-date.

As of 06-Nov, Medicamen Biotech Ltd's stock price is rising at 396.05, with a recent increase of 2.98%. The stock has shown strong short-term performance, gaining 12.51% over the last five days, but has underperformed year-to-date with a decline of 22.23% compared to the Sensex's gain.

As of October 23, 2025, Medicamen Biotec is considered very expensive with a PE ratio of 52.55 and significantly higher valuation metrics compared to peers like Sun Pharma and Cipla, while also underperforming the Sensex with a year-to-date return of -27.87%.

As of 23-Oct, Medicamen Biotech Ltd's stock price has risen to Rs 367.30, reflecting a 13.08% increase today, but it has a year-to-date decline of 27.87% and a significant drop of 59.59% over the past three years. Despite strong short-term gains, declining investor participation and long-term volatility may pose risks for future stability.

As of 15-Oct, Medicamen Biotech Ltd's stock price is rising to Rs 319.00, up 4.33% after two days of decline, with increased investor interest indicated by a 118.53% rise in delivery volume. Despite this short-term recovery, the stock remains below long-term moving averages and has underperformed over the past month and year.

As of October 9, 2025, Medicamen Biotec is considered overvalued with a PE ratio of 44.10 and poor stock performance, significantly lagging behind its peers and the Sensex.

As of October 7, 2025, Medicamen Biotec is fairly valued with a PE ratio of 42.42 and an EV to EBITDA of 28.76, positioning it competitively against peers like Sun Pharma and Cipla, despite a year-to-date return of -41.78% compared to the Sensex's 4.85%.